SEC 13F Intelligence

Managers / Q3 2024 · view latest →

Lion Point Capital, LP

CIK 0001643354 · 375 PARK AVE, SUITE 2609, NEW YORK, NY, 10152 · 212-356-6200

Reported Value
$45M
Q3 2024
Positions
25
Filings on Record
31
2019–present window
Filed
Nov 14, 2024
original filing

Summary

Lion Point Capital, LP reported $45M in U.S.-listed holdings across 25 positions for Q3 2024.

Its largest position, IM8N, represents 8.5% of the portfolio.

Compared with Q2 2024, the fund opened 4 new positions and exited 6.

Portfolio Metrics

Turnover
+10.4%
vs prior filed quarter
Top-10 Concentration
+43.5%
share of reported value
Largest Position
+8.5%
Insmed
New / Exited
4 / 6
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $636MQ4 ’18Q1 ’19: $1.1BQ2 ’19: $1.0BQ3 ’19: $897MQ4 ’19: $1.1BQ4 ’19Q1 ’20: $379MQ2 ’20: $412MQ3 ’20: $456MQ4 ’20: $519MQ4 ’20Q1 ’21: $550MQ2 ’21: $579MQ3 ’21: $533MQ4 ’21: $373MQ4 ’21Q1 ’22: $431MQ2 ’22: $878MQ3 ’22: $454MQ4 ’22: $703MQ4 ’22Q1 ’23: $243MQ2 ’23: $221MQ3 ’23: $224MQ4 ’23: $200MQ4 ’23Q1 ’24: $179MQ2 ’24: $55MQ3 ’24: $45MQ4 ’24: $19MQ4 ’24Q1 ’25: $16MQ2 ’25: $15MQ3 ’25: $18MQ4 ’25: $19MQ4 ’25Q1 ’26: $17Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 48.3%ETP: 40.6%Other: 11.1%
  • Common Stock · 48.3% · $22M
  • ETP · 40.6% · $18M
  • Other · 11.1% · $5M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
BIOHAVEN LTDNEW+35.4K35.4K+$2M$2M
IRONDISC MEDICINE INCNEW+7.7K7.7K+$378,378$378,378
BNTCBENITEC BIOPHARMA INCNEW+39.0K39.0K+$358,410$358,410
ARQTARCUTIS BIOTHERAPEUTICS INCNEW+35.1K35.1K+$326,430$326,430
BLUEBIRD BIO INCADDED+900.0K1.58M+$152,364$819,904
SPDR SER TRSOLD OUT−50.0K0−$5M$0
NBIXNEUROCRINE BIOSCIENCES INCSOLD OUT−8.3K0−$1M$0
ENPHYS ACQUISITION CORPSOLD OUT−78.1K0−$857,813$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2024

23 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1IM8NINSMED INChistory →COM PAR $.018.49%$4M52.2K
2GONGERON CORPhistory →COM6.37%$3M630.0K
3ARDXARDELYX INChistory →COM5.68%$3M370.0K
4MISTMILESTONE PHARMACEUTICALS INhistory →COM5.60%$3M1.65M
5BIOHAVEN LTDCOM3.94%$2M35.4K
6KINIKSA PHARMACEUTICALS LTDORD SHS CL A3.42%$2M61.4K
7BBIOBRIDGEBIO PHARMA INChistory →COM2.78%$1M49.0K
8MARINUS PHARMACEUTICALS INCCOM NEW2.72%$1M693.8K
9FRXFENNEC PHARMACEUTICALS INChistory →COM2.39%$1M215.0K
10MLYSMINERALYS THERAPEUTICS INChistory →COM2.13%$956,69079.0K
11SNDXSYNDAX PHARMACEUTICALS INChistory →COM1.98%$889,35046.2K
12AVADEL PHARMACEUTICALS PLCCOM SHS1.87%$839,36064.0K
13BLUEBIRD BIO INCCOM1.83%$819,9041.58M
14RGNXREGENXBIO INChistory →COM1.35%$605,79857.8K
15JSPRJASPER THERAPEUTICS INChistory →COM NEW1.34%$601,92032.0K
16IRONDISC MEDICINE INCCOM0.84%$378,3787.7K
17BNTCBENITEC BIOPHARMA INCCOM NEW0.80%$358,41039.0K
18ARQTARCUTIS BIOTHERAPEUTICS INCCOM0.73%$326,43035.1K
19MCRB1EURSERES THERAPEUTICS INCCOM0.72%$322,394340.8K
20LUMOS PHARMA INCCOM0.34%$153,20939.6K
21MSFTMICROSOFT CORPCOM0.10%$43,030100
22SPRUCE BIOSCIENCES INCCOM0.08%$35,61875.0K
23GOOGALPHABET INCCAP STK CL C0.04%$16,719100

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$17M35May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$19M39Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$18M27Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$15M19Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$16M21May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$19M19Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$45M25Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$55M27Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$179M32May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$200M30Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$224M31Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$221M30Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$243M31May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$703M32Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$454M41Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$878M40Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$431M35May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$373M33Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$533M38Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$579M34Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$550M30May 19, 2021RESTATEMENTchanges · EDGAR ↗
Q4 2020$519M24Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$456M24Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$412M24Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$379M25May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.1B26Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$897M26Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$1.0B24Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.1B24May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$636M35Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.